ProMIS Neurosciences (PMN) announced that the independent Data and Safety Monitoring Board, DSMB, for its ongoing PRECISE-AD Phase 1b clinical trial has unanimously recommended that the Company proceed to the third and final dose escalation cohort in this trial of PMN310 for the treatment of AD. The recommendation followed a review of available safety data through Cohort 2, which has now been fully enrolled, with no cases of amyloid-related imaging abnormalities observed to date. Enrollment of patients into Cohort 3 is now underway, keeping the Company on track to deliver 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- ProMIS Neurosciences Announces At The Market Offering
- ProMIS Neurosciences: Advancements in Alzheimer’s Treatment and Strong Financial Positioning Drive Buy Rating
- ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss
- ProMIS Neurosciences files $50M mixed securities shelf
- ProMIS Neurosciences reports Q2 EPS (29c) vs (13c) last year